Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aanchal Sugandh

SHOCKING: Charles river laboratories q3 2026 earnings what to expect - What They Never Told You

Founded in 1947, Charles River Laboratories International, Inc. (CRL) is a pharmaceutical research services company that now commands a market cap of nearly $16.5 billion. Its portfolio covers laboratory testing, drug discovery, preclinical development, safety assessment, research models, cell therapy development, and manufacturing, giving the company a broad presence across the drug development process.

The Wilmington, Massachusetts-based Charles River is scheduled to report its Q3 FY2026 results on Wednesday, Nov. 4, before the market opens. Analysts are looking for diluted EPS of $2.98, compared with $2.43 in the year-ago quarter. Expectations are buoyed by the company’s recent consistency, with earnings beating analyst estimates in each of the past four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.